{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:40:23Z","timestamp":1791394823017,"version":"4.3.3"},"reference-count":95,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Antiphospholipid syndrome (APS) is an acquired thrombo-inflammatory disease that has morbid and sometimes devastating effects on patients and their families. This review will discuss the most recent international societal treatment guidelines and propose practical management algorithms for various APS sub-types.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>APS represents a disease spectrum. Although thrombosis and pregnancy morbidities are traditional hallmarks of APS, a variety of extra-criteria clinical phenotypes can often be seen, which makes clinical management more challenging. Primary APS thrombosis prophylaxis should take a risk-stratified approach. Although vitamin K antagonists (VKAs) or heparin\/low molecular weight heparin (LMWH) remain the preferred treatment for secondary APS thrombosis prophylaxis, some international society guidelines support the use of direct oral anticoagulants (DOACs) in certain circumstances. Careful monitoring and individualized obstetric care with the use of aspirin and heparin\/LMWH will improve pregnancy outcomes among pregnant individuals with APS. Treatment of microvascular and catastrophic APS remains challenging. While the addition of various immunosuppressive agents is often utilized, further systemic evaluations of their use are warranted before definitive recommendations can be made. Several new therapeutic strategies are on the horizon that might enable more personalized and targeted APS management in the near future.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Although the knowledge of APS pathogenesis has grown in recent years, the management principles and strategies are largely unchanged. There is an unmet need for evaluating pharmacological agents, beyond anticoagulants, that target diverse thromboinflammatory pathways.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000000932","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T05:04:48Z","timestamp":1677819888000},"page":"149-160","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":65,"title":["Antiphospholipid syndrome management: a 2023 update and practical algorithm-based approach"],"prefix":"10.1097","volume":"35","author":[{"given":"Amala","family":"Ambati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason S.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,3,2]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1177\/0961203320950461","article-title":"16th International Congress on Antiphospholipid Antibodies Task Force report on antiphospholipid syndrome treatment trends","volume":"29","author":"Cohen","year":"2020","journal-title":"Lupus"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMra1705454","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"378","author":"Garcia","year":"2018","journal-title":"N Engl J Med"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.05.007","article-title":"The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review","volume":"92","author":"Cervera","year":"2018","journal-title":"J Autoimmun"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/art.40901","article-title":"The epidemiology of antiphospholipid syndrome: a population-based study","volume":"71","author":"Duarte-Garcia","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1006\/jaut.2000.0409","article-title":"Epidemiology of the antiphospholipid antibody syndrome","volume":"15","author":"Petri","year":"2000","journal-title":"J Autoimmun"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1161\/01.STR.32.8.1701","article-title":"beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu heart program","volume":"32","author":"Brey","year":"2001","journal-title":"Stroke"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11926-021-01038-2","article-title":"Epidemiology of antiphospholipid syndrome in the general population","volume":"23","author":"Dabit","year":"2022","journal-title":"Curr Rheumatol Rep"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1002\/acr.24520","article-title":"Development of a new international antiphospholipid syndrome classification criteria phase I\/II report: generation and reduction of candidate criteria","volume":"73","author":"Barbhaiya","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11926-010-0149-3","article-title":"Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand?","volume":"13","author":"Barbhaiya","year":"2011","journal-title":"Curr Rheumatol Rep"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11926-018-0775-8","article-title":"Primary thrombosis prophylaxis in persistently antiphospholipid antibody-positive individuals: where do we stand in 2018?","volume":"20","author":"Zuo","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.thromres.2014.10.013","article-title":"Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant","volume":"135","author":"Pengo","year":"2015","journal-title":"Thromb Res"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood-2011-03-340232","article-title":"Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study","volume":"118","author":"Pengo","year":"2011","journal-title":"Blood"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1177\/0961203314545410","article-title":"Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study","volume":"23","author":"Mustonen","year":"2014","journal-title":"Lupus"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/0961203316657433","article-title":"Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity","volume":"26","author":"Yelnik","year":"2017","journal-title":"Lupus"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1136\/ard.2010.142042","article-title":"Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study","volume":"70","author":"Ruffatti","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1002\/art.22663","article-title":"Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals","volume":"56","author":"Erkan","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.autrev.2013.10.014","article-title":"Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis","volume":"13","author":"Arnaud","year":"2014","journal-title":"Autoimmun Rev"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.autrev.2014.10.019","article-title":"Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies","volume":"14","author":"Arnaud","year":"2015","journal-title":"Autoimmun Rev"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1136\/ard.2010.135525","article-title":"Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome","volume":"70","author":"Lopez-Pedrera","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa0900241","article-title":"A randomized trial of rosuvastatin in the prevention of venous thromboembolism","volume":"360","author":"Glynn","year":"2009","journal-title":"N Engl J Med"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/0961203317716787","article-title":"Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies","volume":"27","author":"Watanabe","year":"2018","journal-title":"Lupus"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1136\/annrheumdis-2013-203622","article-title":"A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients","volume":"73","author":"Erkan","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","article-title":"EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome","volume":"81","author":"Drosos","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1161\/01.CIR.96.12.4380","article-title":"Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice","volume":"96","author":"Edwards","year":"1997","journal-title":"Circulation"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1182\/blood-2008-03-144204","article-title":"Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers","volume":"112","author":"Rand","year":"2008","journal-title":"Blood"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"576e7","DOI":"10.1016\/j.ajog.2011.06.064","article-title":"Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression","volume":"205","author":"Wu","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"7084","DOI":"10.1080\/14767058.2021.1943656","article-title":"Effect of hydroxychloroquine on antiphospholipid antibodies-inhibited endometrial angiogenesis","volume":"35","author":"Dong","year":"2022","journal-title":"J Matern Fetal Neonatal Med"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/art.24232","article-title":"Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies","volume":"61","author":"Tektonidou","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/0961203317724219","article-title":"Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease","volume":"27","author":"Erkan","year":"2018","journal-title":"Lupus"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"102491","DOI":"10.1016\/j.autrev.2020.102491","article-title":"The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: a pilot open label randomized prospective study","volume":"19","author":"Kravvariti","year":"2020","journal-title":"Autoimmun Rev"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/rheumatology\/ket313","article-title":"Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS)","volume":"53","author":"Cuadrado","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1056\/NEJMoa035241","article-title":"A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome","volume":"349","author":"Crowther","year":"2003","journal-title":"N Engl J Med"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1538-7836.2005.01340.x","article-title":"A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)","volume":"3","author":"Finazzi","year":"2005","journal-title":"J Thromb Haemost"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/art.23109","article-title":"A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies","volume":"57","author":"Ruiz-Irastorza","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1182\/bloodadvances.2017008185","article-title":"Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy","volume":"1","author":"Jackson","year":"2017","journal-title":"Blood Adv"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, noninferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"Ordi-Ros","year":"2019","journal-title":"Ann Intern Med"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/bloodadvances.2021005808","article-title":"Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial","volume":"6","author":"Woller","year":"2022","journal-title":"Blood Adv"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"715878","DOI":"10.3389\/fcvm.2021.715878","article-title":"Use of direct oral anticoagulants in patients with antiphospholipid syndrome: a systematic review and comparison of the international guidelines","volume":"8","author":"Pastori","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"1901647","DOI":"10.1183\/13993003.01647-2019","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): the Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC)","volume":"54","author":"Konstantinides","year":"2019","journal-title":"Eur Respir J"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/jth.15047","article-title":"Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation","volume":"18","author":"Devreese","year":"2020","journal-title":"J Thromb Haemost"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjh.16308","article-title":"Addendum to British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid syndrome, 2012: use of direct acting oral anticoagulants","volume":"189","author":"Arachchillage","year":"2020","journal-title":"Br J Haematol"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"102901","DOI":"10.1016\/j.autrev.2021.102901","article-title":"Pregnancy outcome predictors in antiphospholipid syndrome: a systematic review and meta-analysis","volume":"20","author":"Walter","year":"2021","journal-title":"Autoimmun Rev"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10067-020-05203-3","article-title":"Clinical features associated with pregnancy outcomes in women with positive antiphospholipid antibodies and previous adverse pregnancy outcomes: a real-world prospective study","volume":"40","author":"Li","year":"2021","journal-title":"Clin Rheumatol"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"e000131","DOI":"10.1136\/lupus-2015-000131","article-title":"Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results","volume":"3","author":"Yelnik","year":"2016","journal-title":"Lupus Sci Med"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.thromres.2011.02.006","article-title":"The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis","volume":"128","author":"Abou-Nassar","year":"2011","journal-title":"Thromb Res"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1002\/art.34402","article-title":"Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies","volume":"64","author":"Lockshin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R52-20250526","article-title":"Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study","volume":"216","author":"Saccone","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"R53-20250526","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood-2013-08-522623","article-title":"Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study","volume":"123","author":"Bouvier","year":"2014","journal-title":"Blood"},{"key":"R54-20250526","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1093\/rheumatology\/ker139","article-title":"Risk factors for pregnancy failure in patients with antiphospholipid syndrome treated with conventional therapies: a multicentre, case\u2013control study","volume":"50","author":"Ruffatti","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"R55-20250526","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0002-9378(97)70409-5","article-title":"Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Organizing Group of the Antiphospholipid Antibody Treatment Trial","volume":"176","author":"Cowchock","year":"1997","journal-title":"Am J Obstet Gynecol"},{"key":"R56-20250526","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3899\/jrheum.120576","article-title":"Treatment of 139 pregnancies in antiphospholipid-positive women not fulfilling criteria for antiphospholipid syndrome: a retrospective study","volume":"40","author":"Del Ross","year":"2013","journal-title":"J Rheumatol"},{"key":"R57-20250526","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1080\/01443610500443352","article-title":"Anticardiolipin antibodies in Jamaican primiparae","volume":"26","author":"Kahwa","year":"2006","journal-title":"J Obstet Gynaecol"},{"key":"R58-20250526","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMoa1704559","article-title":"Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia","volume":"377","author":"Rolnik","year":"2017","journal-title":"N Engl J Med"},{"key":"R59-20250526","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/art.41191","article-title":"2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R60-20250526","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0002-9378(96)70610-5","article-title":"Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone","volume":"174","author":"Kutteh","year":"1996","journal-title":"Am J Obstet Gynecol"},{"key":"R61-20250526","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bmj.314.7076.253","article-title":"Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)","volume":"314","author":"Rai","year":"1997","journal-title":"BMJ"},{"key":"R62-20250526","first-page":"CR132","article-title":"The role of aspirin versus aspirin and heparin in cases of recurrent abortions with raised anticardiolipin antibodies","volume":"12","author":"Goel","year":"2006","journal-title":"Med Sci Monit"},{"key":"R63-20250526","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00404-011-2055-y","article-title":"Bemiparin versus low dose aspirin for management of recurrent early pregnancy losses due to antiphospholipd antibody syndrome","volume":"285","author":"Alalaf","year":"2012","journal-title":"Arch Gynecol Obstet"},{"key":"R64-20250526","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3899\/jrheum.080763","article-title":"Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial","volume":"36","author":"Laskin","year":"2009","journal-title":"J Rheumatol"},{"key":"R65-20250526","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/00006250-200212000-00032","article-title":"Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment","volume":"100","author":"Farquharson","year":"2002","journal-title":"Obstet Gynecol"},{"key":"R66-20250526","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.autrev.2014.02.003","article-title":"14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome","volume":"13","author":"de Jesus","year":"2014","journal-title":"Autoimmun Rev"},{"key":"R67-20250526","first-page":"CD012852","article-title":"Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss","volume":"5","author":"Hamulyak","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"R68-20250526","doi-asserted-by":"crossref","first-page":"17103","DOI":"10.1038\/nrdp.2017.103","article-title":"Antiphospholipid syndrome","volume":"4","author":"Schreiber","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"R69-20250526","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1177\/0961203312451335","article-title":"Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study","volume":"21","author":"Fischer-Betz","year":"2012","journal-title":"Lupus"},{"key":"R70-20250526","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/bdrc.21105","article-title":"Epidemiology of venous thromboembolism (VTE) associated with pregnancy","volume":"105","author":"Parunov","year":"2015","journal-title":"Birth Defects Res C Embryo Today"},{"key":"R71-20250526","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejim.2021.12.013","article-title":"Venous thromboembolism during pregnancy and postpartum period","volume":"97","author":"Bukhari","year":"2022","journal-title":"Eur J Intern Med"},{"key":"R72-20250526","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/acr.24468","article-title":"Characteristics of patients with antiphospholipid antibody positivity in the APS ACTION International Clinical Database and Repository","volume":"74","author":"Sevim","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R73-20250526","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/art.41891","article-title":"Expert perspective: management of microvascular and catastrophic antiphospholipid syndrome","volume":"73","author":"Erkan","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R74-20250526","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3389\/fimmu.2019.00941","article-title":"Cardiac manifestations of antiphospholipid syndrome with focus on its primary form","volume":"10","author":"Kolitz","year":"2019","journal-title":"Front Immunol"},{"key":"R75-20250526","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1191\/0961203303lu391oa","article-title":"Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report","volume":"12","author":"Lockshin","year":"2003","journal-title":"Lupus"},{"key":"R76-20250526","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.semarthrit.2015.09.005","article-title":"Cardiac involvement in antiphospholipid syndrome: the diagnostic role of noninvasive cardiac imaging","volume":"45","author":"Mavrogeni","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"R77-20250526","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/0961203320951260","article-title":"16th International Congress on Antiphospholipid Antibodies Task Force report on catastrophic antiphospholipid syndrome","volume":"29","author":"Cervera","year":"2020","journal-title":"Lupus"},{"key":"R78-20250526","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/jth.14192","article-title":"McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome","volume":"16","author":"Legault","year":"2018","journal-title":"J Thromb Haemost"},{"key":"R79-20250526","first-page":"346","article-title":"The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus","volume":"34","author":"Bayraktar","year":"2007","journal-title":"J Rheumatol"},{"key":"R80-20250526","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood-2018-01-785840","article-title":"Chimeric antigen receptor-modified T cells: CD19 and the road beyond","volume":"131","author":"Salter","year":"2018","journal-title":"Blood"},{"key":"R81-20250526","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1111\/bjh.16266","article-title":"Chimeric antigen receptor T-cell therapy's role in antiphospholipid syndrome: a case report","volume":"188","author":"Schmelz","year":"2020","journal-title":"Br J Haematol"},{"issue":"(suppl 9)","key":"R82-20250526","article-title":"Chimeric autoantigen-T cell receptor (CATCR)-T cell therapies to selectively target autoreactive B cells [abstract]","volume":"74","author":"Mog","year":"2022","journal-title":"Arthritis Rheum"},{"key":"R83-20250526","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrrheum.2011.52","article-title":"Pathogenesis of antiphospholipid syndrome: understanding the antibodies","volume":"7","author":"Meroni","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"R84-20250526","doi-asserted-by":"crossref","first-page":"230742","DOI":"10.5402\/2012\/230742","article-title":"Interleukin 10 and tumor necrosis factor-alpha in pregnancy: aspects of interest in clinical obstetrics","volume":"2012","author":"Brogin Moreli","year":"2012","journal-title":"ISRN Obstet Gynecol"},{"key":"R85-20250526","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.semarthrit.2019.02.006","article-title":"Treatment of refractory poor aPL-related obstetric outcomes with TNF-alpha blockers: maternal-fetal outcomes in a series of 18 cases","volume":"49","author":"Alijotas-Reig","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"R87-20250526","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00281-022-00916-w","article-title":"Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome","volume":"44","author":"Knight","year":"2022","journal-title":"Semin Immunopathol"},{"issue":"(1\u20132)","key":"R88-20250526","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2013.05.001","article-title":"Defibrotide: properties and clinical use of an old\/new drug","volume":"59","author":"Pescador","year":"2013","journal-title":"Vascul Pharmacol"},{"key":"R89-20250526","first-page":"399","article-title":"Defibrotide in vitro inhibits neutrophil activation by a Ca++-involving mechanism","volume":"9","author":"Di Perri","year":"1987","journal-title":"Int J Tissue React"},{"key":"R90-20250526","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/art.42017","article-title":"Defibrotide inhibits antiphospholipid antibody-mediated neutrophil extracellular trap formation and venous thrombosis","volume":"74","author":"Ali","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"R91-20250526","first-page":"2006","article-title":"Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator","volume":"29","author":"Burcoglu-O\u2019Ral","year":"2002","journal-title":"J Rheumatol"},{"key":"R92-20250526","doi-asserted-by":"crossref","first-page":"e149149","DOI":"10.1172\/jci.insight.149149","article-title":"Endothelium-protective, histone-neutralizing properties of the polyanionic agent defibrotide","volume":"6","author":"Shi","year":"2021","journal-title":"JCI Insight"},{"key":"R93-20250526","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41467-019-09801-x","article-title":"Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome","volume":"10","author":"Ali","year":"2019","journal-title":"Nat Commun"},{"key":"R94-20250526","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-lived autoreactive plasma cells drive persistent autoimmune inflammation","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"R95-20250526","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"R96-20250526","doi-asserted-by":"crossref","first-page":"667515","DOI":"10.3389\/fimmu.2021.667515","article-title":"Case report: resetting the humoral immune response by targeting plasma cells with daratumumab in anti-phospholipid syndrome","volume":"12","author":"Pleguezuelo","year":"2021","journal-title":"Front Immunol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000932","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T17:19:33Z","timestamp":1748279973000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,2]]},"references-count":95,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000932","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,2]]}}}